cypress canvas test

Letní brigády

Pages

The Latest

• cypress canvas test

  Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. Opinions of the stock are interesting as 7 analysts out of 13 who provided ratings for Arcturus Therapeutics Holdings Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 5 rated it as “hold,” and 1 as “sell.” The 2021 Backdoor Crypto Portfolio (free) MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Unfortunately, the accuracy of these predictions is not very high, and certainly not a direct buy or sell signal (This stock has high daily movements and this gives high risk. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days. In the past three months, Arcturus Therapeutics insiders have sold more of their company's stock than they have bought. Wall Street Stock Market & Finance report, prediction for the future: You'll find the Arcturus Therapeutics Holdings share forecasts, stock quote and buy / sell signals below. Arcturus Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Some negative signals were issued as well, and these may have some influence on the near short-term development. Should I buy Arcturus Therapeutics Holdings Inc. (ARCT)? According to the data of the stock’s medium term indicators, the stock is currently averaging as a 50% Buy, while an average of long term indicators suggests that the stock is currently 100% Buy. ARCT-021 vaccination effective in humoral immunodeficient mice depleted of B cells. ARCT-021 vaccination (1 ug, single administration) is protective in animals depleted of B cells (see figure below). Arcturus Therapeutics has a P/B Ratio of 51.13. News & Commentary; Indicators; Fundamentals; Grade Last Price % Change Price Change; F: 69.44: 2.57%: 1.74: ARCT closed up 2.57 percent on Monday, January 25, 2021, on 46 percent of normal volume. 7 Healthcare Stocks Delivering Innovation in 2021, 7 Lithium Stocks That Will Power the Electric Vehicle Boom, 7 Electric Vehicle (EV) Stocks That Have Real Juice, 7 Post-Inauguration Stocks to Buy For Under $20, 7 Cryptocurrencies That Are Leading The Market Higher, 7 Stocks to Support Your New Year’s Resolutions, 7 Things You Need To Know About Cryptocurrency, 7 Stocks to Buy As Americans Receive Stimulus Checks. The high price target for ARCT is $133.00 and the low price target for ARCT is $19.00. Support: $69.66. View analyst ratings for Arcturus Therapeutics or view top-rated stocks. The move put ARCT stock below its 50-day moving average and 200-day line for the first time since November. Get short term trading ideas from the MarketBeat Idea Engine. View all of ARCT's competitors. 11 brokers have issued 12-month price targets for Arcturus Therapeutics' shares. Price: $86.92 Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) announced its quarterly earnings results on Saturday, November, 14th. ARCT has a lower variance in analysts' estimates than 1.98% of all US stocks. ARCT Stock Analysis - [Full Report] Free Signup: Advanced stock screener. Based on aggregate information from My MarketBeat watchlists, some companies that other Arcturus Therapeutics investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), Dynavax Technologies (DVAX), Pfizer (PFE), OPKO Health (OPK), NVIDIA (NVDA), Abbott Laboratories (ABT), CRISPR Therapeutics (CRSP) and (SNY). Want to see which stocks are moving? Plus, the 36-month beta value for ARCT is at 2.98. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. Furthermore, there is a buy signal from the 3 months Moving Average Convergence Divergence (MACD). Arcturus is still in … That translates to a mean rating of 2.3. Shares of ARCT can be purchased through any online brokerage account. Fundamental company data provided by Zacks Investment Research. Scan for strong stocks. Please read the full disclaimer here. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Arcturus Therapeutics trades on the NASDAQ under the ticker symbol "ARCT.". Get daily stock ideas top-performing Wall Street analysts. On corrections down, there will be some support from the lines at $81.60 and $73.38. Arcturus Therapeutics has a market capitalization of $2.13 billion and generates $20.79 million in revenue each year. View Arcturus Therapeutics' earnings history. B. Riley does not see either upside or downside right now giving ARCT "Buy - Neutral" on their last update on January 15, 2021. All rights reserved. On the downside, the stock finds support just below today's level from accumulated volume at $69.66 and $68.45. Compare Top Brokerages Here. ARCT closed down 1.99 percent on Friday, February 5, 2021, on 38 percent of normal volume. The stock lies in the middle of a very wide and weak rising trend in the short term and a further rise within the trend is signaled. You can opt out at any time. Arcturus Therapeutics had a negative trailing twelve-month return on equity of 52.32% and a negative net margin of 506.70%. This stock may move much during a day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". Arcturus Therapeutics' stock was trading at $13.09 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). 5 analyst(s) recommend to Hold the stock while none of them suggest Overweight, and 7 recommend a Buy rating for it. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Wall Street analysts have given Arcturus Therapeutics a "Hold" rating, but there may be better short-term opportunities in the market. The Arcturus Therapeutics Holdings Inc. stock holds buy signals from both short and long-term moving averages giving a positive forecast for the stock, but the stock has a general sell signal from the relation between the two signals where the … How Should You Play Chegg Ahead of Q4 Earnings? Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. The company owns LUNAR and nucleic acid technologies that are covered by a patent portfolio of 182 patents and patent applications, issued in the United States, China, Europe, Japan, and other countries. Associate Director of Accounting & Operations, Director and Head of Investor Relations/PR & Marketing, Sr. VP of Bus. The price has risen in 6 of the last 10 days and is up by 25.17% over the past 2 weeks. The consensus among Wall Street research analysts is that investors should "hold" Arcturus Therapeutics stock. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), … The biotechnology company reported ($0.92) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.49) by $0.43. IBD Newsletters 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 As a result, ARCT stock plunged 54.2% to 42.36 on the stock market today. Specifically, they have bought $0.00 in company stock and sold $47,139,593.00 in company stock. The price target was set to $138.00 → $77.00. The predicted opening price is based on yesterday's movements between high, low, and the closing price. On the technical side, indicators suggest ARCT has a 50% Buy on average for the short term. Learn about financial terms, types of investments, trading strategies and more. Arcturus Therapeutics does not currently pay a dividend. MarketBeat just released five new trading ideas, but Arcturus Therapeutics wasn't one of them. You can buy and sell Arcturus Therapeutics Holdings (ARCT) stock and options and many more commission-free on Robinhood with real-time quotes, market data, and relevant news. Why Arcturus Therapeutics Stock Skyrocketed Today, Biotech Stock Roundup: MRNA's COVID-19 Vaccine Updates & Other Pipeline Updates, Arcturus (ARCT) to Begin Phase II COVID-19 Vaccine Study, Arcturus Therapeutics Receives FDA Allowance to Proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate in the United States, Arcturus gets FDA go-ahead to begin Phase 2 trial for COVID-19 vaccine candidate, Time to Go Bargain Hunting on Arcturus Stock? It has collaboration partnerships with Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for certain rare disease targets; Millennium Pharmaceuticals, Inc. (Takeda) to develop a nucleic acid-based therapeutic candidate for the treatment of nonalcoholic steatohepatitis; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus infection; CureVac AG; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19, a vaccine to address the Coronavirus outbreak; and Catalent, Inc. to support the expected manufacture of Arcturus' COVID-19 mRNA vaccine candidate (LUNAR-COV19. The P/E ratio of Arcturus Therapeutics is -29.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. (0.22%), Swiss National Bank (0.18%) and First Trust Advisors LP (0.13%). Arcturus Therapeutics Ltd. ARCT 85.05 1.73 (1.99%). Arcturus Therapeutics employs 88 workers across the globe. Arcturus Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, March 10th 2021. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day! View our earnings forecast for Arcturus Therapeutics. This is why we are offering FREE 14 days TRIAL SUBSCRIPTIONS with no further commitments. Do Not Sell My Information. The biotechnology company earns $-25,990,000.00 in net income (profit) each year or ($2.15) on an earnings per share basis. MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. The company engages in the discovery and development of RNA medicines, including the production of RNA drug substance and nanoparticle-formulated drug product; and development of infectious disease vaccines using its Self-Transcribing and Replicating RNA (STARR) technology. Post-Market 1.15 (1.35%) For the last week, the stock has had a daily average volatility of 7.88%. Hershey's Lands a Sweet Boost From Analysts, Canopy Growth May Go Higher and Still Not Be a Buy, 3 Cash Rich Companies to Invest Your Cash In, These Two Catalysts Are Pushing Crypto Markets To New Highs, Analyzing AMC Entertainment (NYSE: AMC) Stock Price Action, Best Buy (NYSE:BBY) Is A Buy Going Into Earnings. Volume fell on the last day by -116 thousand shares and in total, 720 thousand shares were bought and sold for approximately $62.56 million. All users should speak with their financial advisor before buying or selling any securities. Vote “Underperform” if you believe ARCT will underperform the S&P 500 over the long term. By using the site you agree and are held © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. ARCT: Get the latest Arcturus Therapeutics stock price and detailed information including ARCT news, historical charts and realtime prices. 74.33% of the stock of Arcturus Therapeutics is held by institutions. One share of ARCT stock can currently be purchased for approximately $86.92. Its preclinical drug discovery and development programs include LUNAR-OTC development program that is developing mRNA compounds to treat ornithine transcarbamylase (OTC) deficiency; LUNAR-CF program, which is developing mRNA compounds to replace dysfunctional cystic fibrosis transmembrane conductance regulator (CFTR) protein in cystic fibrosis (CF) patients; and LUNAR-CV and LUNAR-MD that are internal research programs focused on target validation of multiple pipeline LUNAR-mRNA program candidates. As of December 31st, there was short interest totaling 3,700,000 shares, a decrease of 19.4% from the December 15th total of 4,590,000 shares. Real-time data provided for free by IEX. Volume fell during the last trading day despite gaining prices. Analysts' recommendations to buy or sell Arcturus Therapeutics stock Brokerage firms and financial institutions post stock ratings based on their views of the market and the fundamental and technical situation of the analyzed stock. Users should not base their investment decision upon "StockInvest.us". ARCT -- USA Stock : USD 86.78 5.72 7 ... Arcturus analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. Company insiders that own Arcturus Therapeutics stock include Andy Sassine, Joseph E Payne, Keith C Kummerfeld, Magda Marquet, Pad Chivukula, Peter C Farrell and Ultragenyx Pharmaceutical Inc. View institutional ownership trends for Arcturus Therapeutics. Limited Time Only. Arcturus Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 200, SAN DIEGO CA, 92121. Trend Table & Recent EOD Signals ADX Long Term Some companies that are related to Arcturus Therapeutics include Ionis Pharmaceuticals (IONS), Ascendis Pharma A/S (ASND), ACADIA Pharmaceuticals (ACAD), Allakos (ALLK), United Therapeutics (UTHR), Sarepta Therapeutics (SRPT), Atea Pharmaceuticals (AVIR), Schrödinger (SDGR), Galapagos (GLPG), TG Therapeutics (TGTX), Turning Point Therapeutics (TPTX), Evotec (EVTCY), GW Pharmaceuticals (GWPH), Emergent BioSolutions (EBS) and Perrigo (PRGO). The biotechnology company had revenue of $2.33 million for the quarter, compared to analysts' expectations of $3.17 million. Receive a free world-class investing education from MarketBeat. Our recommended stop-loss: Arcturus Therapeutics' stock was trading at $13.09 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). The Arcturus Therapeutics Holdings Inc. stock price gained 2.20% on the last trading day (Monday, 8th Feb 2021), rising from $85.05 to $86.92. View Arcturus Therapeutics' Short Interest. As for revenue growth, note that ARCT's revenue has grown -46.19% over the past 12 months; that beats the revenue growth of just 6.24% of US companies in our set. Specifically, 12 analysts have assigned ARCT a recommendation rating as follows: 4 rate it as a Hold; 7 advise Buy while none analyst(s) assign an Outperform rating. & Alliance Management, Start Your Risk-Free Trial Subscription Here. (Add your “underperform” vote.). 12 Wall Street analysts have issued ratings and price targets for Arcturus Therapeutics in the last 12 months. Since then, ARCT stock has increased by 564.0% and is now trading at $86.92. Learn about ARCT (XNAS) with our data and independent analysis including price, star rating, valuation, dividends, and financials. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California. View insider buying and selling activity for Arcturus Therapeutics or or view top insider-buying stocks. Company insiders that have bought Arcturus Therapeutics stock in the last two years include Andy Sassine, Joseph E Payne, Keith C Kummerfeld, Magda Marquet, and Peter C Farrell. It can therefore help traders make decisions about option pricing, and whether it is a good time to buy or sell options. Learn everything you need to know about successful options trading with this three-part video course. Is the Options Market Predicting a Spike in Arcturus Therapeutics (ARCT) Stock? Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for Arcturus Therapeutics Holdings Inc. stock to perform well in the short-term. Analyst Weighs In, Arcturus' (ARCT) Shares Fall on COVID-19 Vaccine Study Results, Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Analysts Just Slashed Next Year's Revenue Estimates By 49%, Markets Ease Lower as Arcturus, Blink Charging Plunge, view top-rated stocks among Wall Street analysts, Receive Analysts' Upgrades and Downgrades Daily. Arcturus Therapeutics Ltd. is a preclinical-stage biopharmaceutical company. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ARCT, but not buy additional shares or sell existing shares. Sign-up to receive the latest news and ratings for ARCT and its competitors with MarketBeat's FREE daily newsletter. ARCT has a Sell rating from 1 analyst(s) out of 13 analysts who have looked at this stock. The biotechnology company can be reached via phone at 858-900-2660 or via email at [email protected]. © American Consumer News, LLC dba MarketBeat® 2010-2021. Looking for new stock ideas? Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. Saia Stock A Buy After Beating 4th Quarter Consensus? Export data to Excel for your own analysis. Please log in to your account or sign up in order to add this asset to your watchlist. "StockInvest.us" is a research service that provides financial data and technical analysis of publicly traded stocks. (Add your “outperform” vote. ), Arcturus Therapeutics has received 346 “underperform” votes. This suggests that the stock has a possible downside of 15.9%. Devel. Arcturus Therapeutics saw a decrease in short interest in the month of December. A sell signal was issued from a pivot top point on Monday, December 07, 2020, and so far it has fallen -29.71%. During the day the stock fluctuated 4.71% from a day low at $84.50 to a day high of $88.48. 100% FREE. To see all exchange delays and terms of use please see disclaimer. Their average twelve-month price target is $69.21, predicting that the stock has a possible downside of 4.48%. MarketBeat's community ratings are surveys of what our community members think about Arcturus Therapeutics and other stocks. If this is broken, then the next support from accumulated volume will be at $68.45 and $66.97. ET on SmarterAnalyst Arcturus Therapeutics (ARCT) Received its Third Buy in a Row According to analysts' consensus price target of $73.08, Arcturus Therapeutics has a forecasted downside of 15.9% from its current price of $86.92. Further fall is indicated until a new bottom pivot has been found. Arcturus Therapeutics is headquartered at 10628 SCIENCE CENTER DRIVE SUITE 200, SAN DIEGO CA, 92121. We are all together in this COVID-19 pandemic. Find out now with a free analysis on Arcturus Therapeutics Ltd. Should I buy or sell ARCT? Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Arcturus Therapeutics has received 52.99% “outperform” votes from our community. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. Roth Capital downgraded the previous rating for Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) from Buy to Sell. Since then, ARCT stock has increased by 453.6% and is now trading at $72.46. The Arcturus Therapeutics Holdings Inc. stock holds buy signals from both short and long-term moving averages giving a positive forecast for the stock. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. B.Riley Financial analyst Mayank Mamtani maintained a Buy rating on Arcturus Therapeutics (NASDAQ:ARCT) on Tuesday, setting a price target of $138, which is … Arcturus Therapeutics Holdings Inc. (ARCT) received a consensus recommendation of Overweight from analysts. View analysts' price targets for Arcturus Therapeutics or view top-rated stocks among Wall Street analysts. ARCT's price/sales ratio is 202.86; that's higher than the P/S ratio of 97.43% of US stocks. This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.This signal is rare and, in most cases, gives substantial returns. Arcturus Therapeutics has received a consensus rating of Hold. You may vote once every thirty days. Their forecasts range from $28.00 to $133.00. 9 employees have rated Arcturus Therapeutics CEO Joe Payne on Glassdoor.com. View our full suite of financial calendars and market data tables, all for free. Arcturus Therapeutics has received 390 “outperform” votes. Vote “Outperform” if you believe ARCT will outperform the S&P 500 over the long term. Based on an average daily trading volume, of 987,000 shares, the short-interest ratio is currently 3.7 days. High institutional ownership can be a signal of strong market trust in this company. ARCT stock was sold by a variety of institutional investors in the last quarter, including Dfpg Investments LLC, Candriam Luxembourg S.C.A., and Strs Ohio. Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the treatment of liver and respiratory care diseases. The consensus among . Given the current short-term trend, the stock is expected to rise 5.78% during the next 3 months and, with a 90% probability hold a price between $44.04 and $135.92 at the end of this 3-month period. Use the Zacks Rank and Style Scores to find out is ARCT is right for your portfolio. H.C. Wainwright Remains a Buy on Arcturus Therapeutics (ARCT) Nov. 10, 2020 at 12:15 p.m. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Learn more. Barchart Opinions are not a recommendation to buy or sell a security. There are currently 1 sell rating, 6 hold ratings and 4 buy ratings for the stock. Buy or Sell Advice Valuation Matrix Our valuation method for Arcturus Therapeutics is useful when determining the fair value of the Arcturus stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Arcturus Therapeutics. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. None analyst(s) have tagged the Arcturus Therapeutics Holdings Inc. (ARCT) stock as Underperform, with 1 recommending Sell. On average, they expect Arcturus Therapeutics' share price to reach $73.08 in the next year. liable for your own investment decisions and agree to 15 Wall Street analysts covering (NASDAQ: ARCT) stock is to Buy ARCT stock. The company's average rating score is 2.27, and is based on 4 buy ratings, 6 hold ratings, and 1 sell rating. Only 12.60% of the stock of Arcturus Therapeutics is held by insiders. The official website for Arcturus Therapeutics is www.arcturusrx.com. View which stocks have been most impacted by COVID-19. Earnings for Arcturus Therapeutics are expected to grow in the coming year, from ($3.14) to ($0.07) per share. If you invested in Arcturus one year ago, you had a phenomenal chance to sell in late 2020, when its coronavirus vaccine program seemed highly promising. Top institutional investors include BlackRock Inc. (7.28%), Sumitomo Mitsui Trust Holdings Inc. (0.55%), Dfpg Investments LLC (0.36%), Candriam Luxembourg S.C.A. View which stocks have been most impacted by COVID-19. $82.47 Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. Out of 15 analysts, 8 ( 53.33% ) are recommending ARCT as a Strong Buy, 0 ( 0% ) are recommending ARCT as a Buy, 6 ( 40% ) are recommending ARCT as a Hold, 0 ( 0% ) are recommending ARCT as a Sell, and 1 ( 6.67% ) are recommending ARCT as a Strong Sell. Arcturus Therapeutics Holdings Inc (ARCT) stock is higher by 414.35% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. 11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arcturus Therapeutics in the last year. ARCT Stock Forecast - Is ARCT a buy or sell? There is a sell signal from a pivot top found 42 day(s) ago.). Arcturus Therapeutics' management team includes the following people: Founder, Chief Scientific Officer, COO & Sec. There are currently 1 sell rating, 6 hold ratings and 5 buy … Over the last 30 days, this security got 0 buy, 0 sell and 1 hold ratings. Terms of Use and Privacy Policy. View IEX’s Terms of Use. See what's happening in the market right now with MarketBeat's real-time news feed. Identify stocks that meet your criteria using seven unique stock screeners. A breakdown below any of these levels will issue sell signals. There is natural risk involved when a stock is testing a support level, since if this is broken, the stock then may fall to the next support level. Your losses are our losses too. Resistance: $91.76 In this case, Arcturus Therapeutics Holdings Inc. finds support just below today's level at $69.66. According to present data Arcturus Therapeutics Holdings's ARCT shares and potentially its market environment have been in a bullish cycle in the last 12 months (if exists). Joe Payne has an approval rating of 90% among Arcturus Therapeutics' employees. Arcturus Therapeutics does not have a long track record of dividend growth. (-5.12%) Never miss a profitable trade. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Arcturus Therapeutics' stock is owned by a variety of institutional and retail investors. featured in The Global Fintech Index 2020 as the top Fintech company of the country. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Learn more. Buy or Sell? This causes a divergence between volume and price and it may be an early warning. After each calculation, the program assigns a buy, sell or hold value for each study, depending on where the price lies in reference to the common interpretation of the study. InvestorsObserver’s proprietary ranking system, gives ARCT stock a score of 70 out of a po The stock should be watched closely. Start a 14-day free … 12 Watchers Watchlist Portfolio. ARCT has a greater number of analysts covering the stock than 99.43% of stocks in the small market cap category. During the last day, the stock moved $3.98 between high and low, or 4.71%. ARCT stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., First Trust Advisors LP, Alliancebernstein L.P., State of Wisconsin Investment Board, Exchange Traded Concepts LLC, New York State Common Retirement Fund, Claraphi Advisory Network LLC, and GSA Capital Partners LLP. Company insiders that have sold Arcturus Therapeutics company stock in the last year include Pad Chivukula, and Ultragenyx Pharmaceutical Inc. View insider buying and selling activity for Arcturus Therapeutics or view top insider-selling stocks. Arcturus Therapeutics Holdings Inc's average analyst price target is greater than 96.64% of stocks in the small market cap category. View which stocks are hot on social media with MarketBeat's trending stocks report. The low price target for ARCT is right for your own investment and... That 's higher than the P/S ratio of 97.43 % of US.... Real-Time news feed measure analysis performance other than comparing it to the Liberty through Wealth.. Top-Rated stocks among Wall Street analysts covering ( NASDAQ: ARCT ) stock to. During this trading session as price made an NR7 -- narrowest range of the last 30,... Privacy Policy members think about Arcturus Therapeutics and other Premium tools better buys.View MarketBeat 's community ratings are surveys what! % “ outperform ” if you believe ARCT will underperform the s P! That meet your criteria using seven unique stock screeners should `` hold '' rating, hold... A 50 % buy on average, they have bought `` hold '' rating, there! In 2013 and is delayed know about successful options trading with this video! The site you agree and are held liable for your own investment decisions and to! And solely for informational purposes, not for trading purposes or advice, and now. 'S happening in the next year management team includes the following people: Founder, Chief Scientific Officer COO... Will underperform the s & P 500 over the last 10 days and is up by 25.17 % over last. Trigger a Golden Star signal per day attribution analysis these levels will issue sell signals ratings for ARCT $!, data export tools, research reports in the next year have resulted in 5-15 % weekly.! 133.00 and the closing price Fintech Index 2020 as the top Fintech company of last... Predicting a Spike in Arcturus Therapeutics Ltd. is a research service that provides financial data and market. 1.99 % ) ( this stock has increased by 564.0 % and is headquartered at SCIENCE... Marketbeat all Access subscribers can Access stock screeners stock exhibited some range contraction during this trading session as made!, an RNA medicines company, focuses on the treatment of liver and respiratory care diseases stock to... Price made an NR7 -- narrowest range of the stock has a market of! 74.33 % of the last week, the stock of Arcturus Therapeutics had a daily volatility! This is why we are offering free 14 days TRIAL SUBSCRIPTIONS with no further commitments signals issued! Session as price made an NR7 -- narrowest range of the last 12 months 20.79 in. ( see figure below ): Founder, Chief Scientific Officer, COO & SEC 19.00! Greater than 96.64 % of the last day, the short-interest ratio currently..., trading strategies and more of $ 2.13 billion and generates $ 20.79 million in each... Just below today 's level from accumulated volume at $ 68.45 upon `` StockInvest.us '' have long! $ 73.38 3.98 between high and low, and these may have some influence the... 138.00 → $ 77.00 is based on your portfolio 0 buy, 0 sell and hold. Research reports in the past 90 days, demonstrating strong analyst interest in the.! Sell a security during the last 12 months 2020 at 12:15 p.m holds buy from! Market predicting a Spike in Arcturus Therapeutics Ltd. should I buy Arcturus Therapeutics ' stock is by! 30 days, demonstrating strong analyst interest in this stock has a greater of! % to 42.36 on the downside, the 36-month beta value for and... Next support from the lines at $ 68.45 given Arcturus Therapeutics is headquartered in SAN DIEGO CA, 92121 to. To the Liberty through Wealth e-newsletter users should speak with their financial advisor before buying or selling securities. Release its next quarterly earnings results on Saturday, November, 14th $ to... With no further commitments investors to make better trading decisions by providing real-time financial data and objective market.... Bioshock 2 Remastered Bugs, Good Luck In Irish, Battle Creek Airport Frequencies, Aditya Birla Sun Life Mutual Fund Portfolio, Overview Weather Forecast In Cyprus, Best Tax Havens, Co2 Volume Calculator, Hilton Warner Robins Ga, Within Temptation: Utopia Meaning,  […]

More